Business Context and Reporting Period
Company: Vir Biotechnology, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 9, 2020
Event: Entry into a Material Definitive Agreement with Glaxo Wellcome UK Limited and Beecham S.A. (collectively, "GSK").
The agreement, effective as of April 29, 2020, establishes a collaboration to research, develop, and commercialize products for the prevention, treatment, and prophylaxis of diseases caused by SARS-CoV-2 (COVID-19) and potentially other coronaviruses.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. This document focuses on the terms of a strategic partnership rather than periodic financial performance.
Material Changes and Agreement Terms
The definitive agreement supersedes a preliminary agreement from April 2020 and outlines the following material terms:
- Scope: Collaboration covers three programs:
- Antibody Program: Focused on VIR-7831 and VIR-7832.
- Vaccine Program: Development of vaccines targeting SARS-CoV-2.
- Functional Genomics Program: Products based on CRISPR screening of host targets.
- Roles and Responsibilities:
- Vir Biotechnology: Primarily responsible for development and clinical manufacturing for the Antibody Program and initial development for the Vaccine Program.
- GSK: Primarily responsible for commercialization of the Antibody Program (excluding Greater China), later-stage development/manufacturing/commercialization for the Vaccine Program, and all activities for the Functional Genomics Program.
- Cost Sharing:
- Antibody Products: Vir bears 72.5%; GSK bears 27.5%.
- Vaccine Products: Vir bears 27.5%; GSK bears 72.5%.
- Functional Genomics Products: Costs shared equally (50/50).
- Profit Sharing: Profits and losses are shared in the same ratios as the development costs borne by each party, unless a party opts out.
- Opt-Out Mechanism: Either party may opt out of co-funding obligations at specified development points. The commercializing party must pay royalties to the opt-out party based on net sales or sublicense revenue.
- Commercialization Rights: GSK leads commercialization and books sales. Vir retains a co-promotion right in the U.S. for antibody products, allowing up to 20% of sales details.
Guidance, Outlook, and Risks
Outlook: The collaboration aims to accelerate the development of treatments and vaccines for COVID-19. The agreement includes forward-looking statements regarding the potential benefits of the partnership, the neutralizing effects of VIR-7831 and VIR-7832, and the timeline for clinical trials.
Risks and Contingencies:
- Actual results may differ materially from expectations due to clinical trial outcomes, regulatory approval challenges, and competition.
- Delays or disruptions may occur due to the ongoing COVID-19 pandemic.
- Challenges in identifying new anti-viral antibodies or inhibiting cellular targets.
- Termination rights exist for insolvency, uncured material breach, or mutual agreement.
Investor Verification Checklist
- Verify the specific terms of the manufacturing technology transfer with WuXi Biologics and Biogen Inc. referenced in the cost-sharing section.
- Confirm the status of clinical trials for VIR-7831 and VIR-7832 and their regulatory timelines.
- Review the full text of the definitive agreement (to be filed as an exhibit) for detailed opt-out triggers and royalty calculation methodologies.
- Assess the impact of the 72.5% cost burden on Vir's cash position for the Antibody Program.
- Monitor the joint steering committee's decisions regarding development plans and budgets.